专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US09943401B2 Therapeutic device for pain management and vision 有权
公开(公告)号：US09943401B2
公开(公告)日：2018-04-17
申请号：US12384659
申请日：2009-04-06
申请人： Eugene de Juan, Jr. , Cary J. Reich , Stephen Boyd , Yair Alster , David Sierra , Hanson S. Gifford , Jose D. Alejandro , Richard L. Lindstrom , K. Angela Macfarlane , Douglas Sutton , John Anthony Scholl
发明人： Eugene de Juan, Jr. , Cary J. Reich , Stephen Boyd , Yair Alster , David Sierra , Hanson S. Gifford , Jose D. Alejandro , Richard L. Lindstrom , K. Angela Macfarlane , Douglas Sutton , John Anthony Scholl
IPC分类号： A61F2/14 , A61F9/00 , G02C7/04
CPC分类号： A61F2/142 , A61F2/14 , A61F9/00 , A61F2250/0067 , G02C7/047
摘要： A therapeutic lens for the treatment of an epithelial defect comprises a layer of therapeutic material disposed over the stroma and/or Bowman's membrane to inhibit water flow from the tear liquid to the stroma and/or Bowman's membrane, such that corneal deturgescence can be restored to decrease corneal swelling and light scattering. The layer may cover and protect nerve fibers to decrease pain. The layer may comprise an index of refraction to inhibit light scatter from an anterior surface of the stroma and/or Bowman's membrane. The lens may comprise a curved anterior surface that provides functional vision for the patient when the epithelium regenerates. The layer of therapeutic material can be positioned on the eye in many ways, for example with a spray that is cured to adhere the layer to the exposed surface of the stroma and/or Bowman's membrane.

2. 发明申请

US20100036488A1 Therapeutic device for pain management and vision 有权
标题翻译：用于疼痛管理和视力的治疗装置
公开(公告)号：US20100036488A1
公开(公告)日：2010-02-11
申请号：US12384659
申请日：2009-04-06
申请人： Eugene de Juan, JR. , Cary J. Reich , Stephen Boyd , Yair Alster , David Sierra , Hanson S. Gifford , Jose D. Alejandro , Richard L. Lindstrom , K. Angela Macfariane , Douglas Sutton , John Anthony
发明人： Eugene de Juan, JR. , Cary J. Reich , Stephen Boyd , Yair Alster , David Sierra , Hanson S. Gifford , Jose D. Alejandro , Richard L. Lindstrom , K. Angela Macfariane , Douglas Sutton , John Anthony
IPC分类号： A61F2/14
CPC分类号： A61F2/142 , A61F2/14 , A61F9/00 , A61F2250/0067 , G02C7/047
摘要： A therapeutic lens for the treatment of an epithelial defect comprises a layer of therapeutic material disposed over the stroma and/or Bowman's membrane to inhibit water flow from the tear liquid to the stroma and/or Bowman's membrane, such that corneal deturgescence can be restored to decrease corneal swelling and light scattering. The layer may cover and protect nerve fibers to decrease pain. The layer may comprise an index of refraction to inhibit light scatter from an anterior surface of the stroma and/or Bowman's membrane. The lens may comprise a curved anterior surface that provides functional vision for the patient when the epithelium regenerates. The layer of therapeutic material can be positioned on the eye in many ways, for example with a spray that is cured to adhere the layer to the exposed surface of the stroma and/or Bowman's membrane.
摘要翻译：用于治疗上皮缺损的治疗镜片包括设置在基质和/或Bowman膜上的治疗材料层，以抑制从泪液到基质和/或Bowman膜的水流，使得可以恢复角膜deturgescence 减少角膜肿胀和光散射。该层可以覆盖并保护神经纤维以减轻疼痛。该层可以包括折射率以抑制从基质和/或Bowman膜的前表面的光散射。透镜可以包括弯曲的前表面，当上皮再生时，该前表面为患者提供功能视觉。治疗材料层可以以许多方式定位在眼睛上，例如通过固化以将该层粘附到基质和/或Bowman膜的暴露表面上的喷雾。

3. 发明授权

US5002569A Intraocular lens 失效
标题翻译：人工晶状体
公开(公告)号：US5002569A
公开(公告)日：1991-03-26
申请号：US529883
申请日：1990-05-29
申请人： Richard L. Lindstrom
发明人： Richard L. Lindstrom
IPC分类号： A61F2/16
CPC分类号： A61F2/1613
摘要： An intraocular lens denoted as a YAG dimpled lens or dimpled YAG lens, which includes a barrier rim and a YAG spacer area in a posterior surface of the lens. The barrier rim is 2-4 mm in longitudinal length and the YAG spacer is 3-4 mm in longitudinal length across the surface diameter of an optic of the intraocular lens. The lens optic can be either plano-convex or bi-convex. A cutout for the dimpled YAG spacer is provided which is either a convave or a substantially rectangular geometrical configuration in the posterior surface of the lens. The YAG spacer can also include a trough or a groove geometrical configuration, such as in the configurations of a Maltese cross, a circular trough or groove, or a circular trough or groove with a Maltese cross therein. The barrier rim is 33% to 80% of the total surface are of the posterior surface of the lens.
摘要翻译：一种称为YAG凹凸透镜或凹凸YAG透镜的眼内透镜，其包括镜片后表面中的屏障边缘和YAG间隔区域。屏障边缘在纵向长度上为2-4mm，并且YAG间隔物在纵向长度上穿过眼内透镜的光学元件的表面直径为3-4mm。透镜光学元件可以是平凸的或双凸的。提供了用于凹凸的YAG间隔件的切口，其是在镜片的后表面中的手链或基本上矩形的几何构型。 YAG间隔物还可以包括槽或凹槽几何构型，例如在马耳他十字架，圆形槽或凹槽的构造中，或者在其中具有马耳他十字的圆形槽或槽。屏障边缘是总表面的33％至80％是透镜的后表面。

4. 发明授权

US4959319A Process of corneal enhancement 失效
标题翻译：角膜增强过程
公开(公告)号：US4959319A
公开(公告)日：1990-09-25
申请号：US311846
申请日：1989-02-17
申请人： Debra L. Skelnik , Richard L. Lindstrom
发明人： Debra L. Skelnik , Richard L. Lindstrom
IPC分类号： C12N5/071
CPC分类号： C12N5/0621
摘要： A process for establishing functional human corneal tissue consisting of an enhanced contact-inhibited endothelial monolayer derived from isolated human corneal endothelial cells with other integral corneal layers remaining intact. The process is divided into four integral parts.1. Isolation of human corneal endothelial cells from donor corneas.2. Establishment of a human corneal endothelial cell line which involves the establishment of primary cell cultures, proliferation, and continued maintenance and subculturing of these cells in vitro.3. The utilization of long term storage of isolated human corneal endothelial cells at -80.degree. C.4. Utilizing these isolated corneal endothelial cells from the above processes to enhance the corneal endothelial monolayer of human donor corneas to be used for penetrating keratoplasty.Two distinct methods of corneal endothelial enhancement may be utilized. In the first method, isolated human corneal endothelial cells are incorporated into the existing donor monolayer and re-establish a contact-inhibited functional monolayer, with a flattened, hexagonal configuration. In this procedure, the donor corneal endothelium remains intact and is supplemented with additional corneal endothelium. In the second method, isolated human corneal endothelial cells are seeded onto a denuded Descement's membrane and re-establish an intact cellular matrix, and form a contact-inhibited functional endothelial monolayer. In this procedure, the donor corneal endothelium is completely removed and replaced with new endothelial cells.
摘要翻译：用于建立功能性人角膜组织的方法，其由来自分离的人角膜内皮细胞的增强的接触抑制内皮单层组成，其余整体角膜层保持完整。该过程分为四个组成部分。 1.从供体角膜分离人角膜内皮细胞。 2.建立人类角膜内皮细胞系，其涉及在体外建立原代细胞培养物，增殖和持续维持和传代培养这些细胞。 3.在-80℃下利用长期保存的孤立人角膜内皮细胞。4.利用上述方法分离的角膜内皮细胞，增强用于穿透角膜移植术的人供体角膜角膜内皮单层。可以使用两种不同的角膜内皮增强方法。在第一种方法中，将孤立的人角膜内皮细胞掺入现有的供体单层中，并重新建立具有扁平六边形构型的接触抑制功能单层。在此过程中，供体角膜内皮保持完整，并补充额外的角膜内皮。在第二种方法中，将分离的人角膜内皮细胞接种到裸露的Descement膜上并重新建立完整的细胞基质，并形成接触抑制功能内皮单层。在此过程中，供体角膜内皮被完全去除，并用新的内皮细胞代替。

5. 发明授权

US4725586A Surgical solution 失效
标题翻译：手术解决方案
公开(公告)号：US4725586A
公开(公告)日：1988-02-16
申请号：US836156
申请日：1986-03-04
申请人： Richard L. Lindstrom , Debra Skelnik
发明人： Richard L. Lindstrom , Debra Skelnik
IPC分类号： A61K31/715 , A61K9/00 , A61K31/70
CPC分类号： A61K9/0048
摘要： A surgical or irrigation solution which provides the anterior and posterior chamber of the eye with protection during surgical procedures that require irrigation. This irrigation solution is composed of a HEPES buffered Eagle's Minimum Essential Media (MEM) with Earle's Salts, without phenol red, supplemented with mixed isomers of 99% pure, chondroitin sulfate, MEM non-essential amino acids, 2-mercaptoethanol, and sodium pyruvate. Other solutions include a balanced salt solution, chondroitin sulfate, buffers and 2-mercaptoethanol. The solution can also be used in other surgical or medical applications.
摘要翻译：一种手术或灌洗液，其在需要灌洗的手术过程中提供眼睛的前房和后房保护。该灌注溶液由具有Earle Salts的HEPES缓冲的Eagle's Minimum Essential Media（MEM），不含酚红，补充99％纯度的混合异构体，硫酸软骨素，MEM非必需氨基酸，2-巯基乙醇和丙酮酸钠。其他溶液包括平衡盐溶液，硫酸软骨素，缓冲液和2-巯基乙醇。该解决方案也可用于其他手术或医疗应用。

6. 发明授权

US08551974B1 Ophthalmic compositions including lubricant, deturgescent agent, and glycosaminoglycan and methods of using the same 有权
标题翻译：眼科组合物，包括润滑剂，止痒剂和糖胺聚糖及其使用方法
公开(公告)号：US08551974B1
公开(公告)日：2013-10-08
申请号：US12802663
申请日：2010-06-11
申请人： Richard L. Lindstrom
发明人： Richard L. Lindstrom
IPC分类号： A61K31/715 , A61K31/70 , A61K47/00
CPC分类号： A61K9/0048 , A61K31/737 , A61K47/10 , A61K47/36 , Y10S514/912 , Y10S514/915
摘要： Ophthalmic compositions are provided that include a lubricant, a deturgescent agent, a glycosaminoglycan, and water. Methods of using the ophthalmic compositions are also provided.
摘要翻译：提供了包括润滑剂，止痒剂，糖胺聚糖和水的眼科组合物。还提供了使用眼用组合物的方法。

7. 发明申请

US20130165419A1 COMBINATION ANTI-INFLAMMATORY OPHTHALMIC COMPOSITIONS 审中-公开
公开(公告)号：US20130165419A1
公开(公告)日：2013-06-27
申请号：US13333534
申请日：2011-12-21
申请人： Richard L. Lindstrom , Kamran Hosseini , Lyle M. Bowman
发明人： Richard L. Lindstrom , Kamran Hosseini , Lyle M. Bowman
IPC分类号： A61K31/573 , A61P27/02 , A61P31/12 , A61P31/04 , A61P27/12 , A61P27/06 , A61P35/00 , A61P33/02 , A61P31/10 , A61P29/00 , A61P27/14
CPC分类号： A61K31/573 , A61K9/0048 , A61K9/08 , A61K31/196 , A61K31/57 , A61K45/06 , A61K2300/00
摘要： Compositions and systems for topical ophthalmic application, which include an aqueous mixture of steroidal and non-steroidal anti-inflammatory agents in a flowable mucoadhesive polymer, for treating inflammation and inflammatory conditions of the eye.

8. 发明授权

US07820639B2 Ophthalmic compositions including lubricant, deturgescent agent, and glycosaminoglycan and methods of using the same 有权
标题翻译：眼科组合物，包括润滑剂，止痒剂和糖胺聚糖及其使用方法
公开(公告)号：US07820639B2
公开(公告)日：2010-10-26
申请号：US11240000
申请日：2005-09-30
申请人： Richard L. Lindstrom
发明人： Richard L. Lindstrom
IPC分类号： A61K31/715 , A61K31/70 , A61K47/00
CPC分类号： A61K9/0048 , A61K31/737 , A61K47/10 , A61K47/36 , Y10S514/912 , Y10S514/915
摘要： Ophthalmic compositions are provided that include a lubricant, a deturgescent agent, a glycosaminoglycan, and water. Methods of using the ophthalmic compositions are also provided.
摘要翻译：提供了包括润滑剂，止痒剂，糖胺聚糖和水的眼科组合物。还提供了使用眼用组合物的方法。

9. 发明授权

US5407669A Method and apparatus of a defined serumfree medical solution 失效
标题翻译：定义的无血液药物溶液的方法和装置
公开(公告)号：US5407669A
公开(公告)日：1995-04-18
申请号：US845660
申请日：1992-03-04
申请人： Richard L. Lindstrom , Debra Skelnik
发明人： Richard L. Lindstrom , Debra Skelnik
IPC分类号： A01N1/02 , A61K31/715 , A61K38/17 , A61K31/74 , C12N5/00
CPC分类号： A01N1/0226 , A01N1/021 , A01N1/0215
摘要： A defined serumfree medical solution for applications in Ophthalmology, that contains one or more cell nutrient supplements which maintains and enhances the preservation of eye tissues, including human corneal tissues at low temperatures (2.degree. C. to 15.degree. C.). This solution is composed of a defined aqueous nutrient and electrolyte solution, supplemented with a glycosaminoglycan(s), a deturgescent agent(s), an energy source(s), a buffer system(s), an antioxidant(s), membrane stabilizing components, antibiotic(s), ATP precursors and nutrient cell supplements.
摘要翻译：一种用于眼科应用的定义的无血液药物溶液，其含有一种或多种细胞营养补充剂，其在低温（2℃至15℃）下维持并增强眼组织的保存，包括人角膜组织。该溶液由限定的水性营养物和电解质溶液组成，补充有糖胺聚糖，一种或多种防腐剂，能量源，缓冲系统，抗氧化剂，膜稳定剂组分，抗生素，ATP前体和营养细胞补充剂。

10. 发明授权

US5204325A Viscoelastic solution 失效
标题翻译：粘弹性溶液
公开(公告)号：US5204325A
公开(公告)日：1993-04-20
申请号：US695332
申请日：1991-05-03
申请人： Richard L. Lindstrom , Debra Skelnik
发明人： Richard L. Lindstrom , Debra Skelnik
IPC分类号： A61K38/18
CPC分类号： A61K38/28 , A61K38/1808
摘要： Viscoelastic solution including a buffered solution, 0.01-8% chondroitin sulfate, 0.1-8% hydroxypropyl methylcellulose, pH adjusted to 6.0-8.0 at a osmolality between 200-400 mOsmol/L. The buffered solution can be HEPES buffered minimum essential media (MEM), phosphate buffer saline (PBS), buffered balanced salt solution, or TC199. A cell growth factor or cell growth supplement is included in the solution.
摘要翻译：包含缓冲溶液的粘弹性溶液，0.01-8％硫酸软骨素，0.1-8％羟丙基甲基纤维素，在200-400mOsmol / L的重量摩尔渗透压浓度下将pH调节至6.0-8.0。缓冲溶液可以是HEPES缓冲的最小必需培养基（MEM），磷酸盐缓冲盐水（PBS），缓冲平衡盐溶液或TC199。细胞生长因子或细胞生长补充剂包括在溶液中。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式